Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tanuj Puri has a total of 123 co-authors. Here are the top co-authors by number of shared publications:

  • Michelle L. Frost

    Institute of Cancer Research Clinical Trials & Statistics Unit (ICR-CTSU), The Institute of Cancer Research, Sutton, United Kingdom

    10 shared publications
  • Glen M. Blake

    Department of Biomedical Engineering, School of Biomedical Engineering and Imaging Sciences, King’s College London, St. Thomas’ Hospital, London, United Kingdom

    9 shared publications
  • Glen Mervyn Blake

    Department of Biomedical Engineering, School of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.

    8 shared publications
  • Ignac Fogelman

    Osteoporosis Research Unit, Guy’s & St Thomas’ Hospital, King’s College London, London, UK

    8 shared publications
  • Amelia E. B. Moore

    Department of Cancer Imaging, and King’s College London and Guy’s and St Thomas’ PET Centre, School of Biomedical Engineering and Imaging Sciences, King’s College London, St. Thomas’ Hospital, London, United Kingdom

    6 shared publications
  • Gary James R. Cook

    School of Biomedical Engineering and Imaging Sciences, King’s College London, London, UK

    6 shared publications

Latest Publications

  • Open Access

    Voxel-Based Dose–Toxicity Modeling for Predicting Post-Radiotherapy Toxicity: A Critical Perspective

    by Tanuj Puri

    This perspective paper critically examines the emerging role of voxel-based analysis (VBA), also referred to as image-based data mining (IBDM), in dose–toxicity modeling for post-radiotherapy toxicity assessment. These techniques offer promising insights into localized organ subregions associated with toxicity, yet their current application faces substantial methodological and validation challenges. Based on prior studies and practical experience, we highlight seven key limitations: (i) lack of clinical validation for dose–toxicity models, (ii) strong dependence of results on statistical method selection (parametric vs. nonparametric), (iii) insensitivity of commonly used tests to uniform dose scaling, (iv) influence of tail selection (one- vs. two-tailed tests) on statistical power, (v) frequent misapplication of permutation testing, (vi) reliance on dose as the sole predictor while neglecting patient-, treatment-, and genomic-level covariates, and (vii) misinterpretation of voxel-wise associations as causal in the absence of appropriate causal inference frameworks. Collectively, these limitations can obscure clinically relevant dose differences, inflate false-positive or false-negative findings, obscure effect direction, introduce confounded associations, and ultimately yield inconsistent identification of high-risk subregions in organs at risk and poor reproducibility across studies. Notably, current univariable VBA/IBDM approaches should be regarded as hypothesis-generating rather than clinical decision-making tools, as unvalidated findings risk premature translation into clinical practice. Advancing personalized radiotherapy requires rigorous outcome validation, integration of multivariable and causal modeling strategies, and incorporation of clinical and genomic data. By moving beyond dose-only predictor models, VBA/IBDM can achieve greater biological relevance, reliability, and clinical utility, supporting more precise and individualized radiotherapy strategies.


  • Open Access

    Sensitivity analysis of dose-response model parameters for the bladder in prostate cancer radiotherapy

    by Tanuj Puri, Tiziana Rancati, Petra Seibold, Adam Webb, Eliana Vasquez Osorio, David Azria, Marie-Pierre Farcy-Jacquet, Jenny Chang-Claude, Alison Dunning, Maarten Lambrecht, et al.


  • Open Access

    Dose-response mapping of bladder and rectum in prostate cancer patients undergoing radiotherapy with and without baseline toxicity correction

    by Tanuj Puri, Tiziana Rancati, Petra Seibold, Adam Webb, Eliana Vasquez Osorio, Andrew Green, Eliana Gioscio, David Azria, Marie-Pierre Farcy-Jacquet, Jenny Chang-Claude, et al.


  • Open Access

    The value of post radiotherapy prostate specific antigen dynamics for prostate cancer risk stratification models

    by Jane Shortall, Eliana Vasquez Osorio, Andrew Green, Kimberley Reeves, David Wong, Tanuj Puri, Peter Hoskin, Ananya Choudhury, Marcel van Herk, Alan McWilliam


  • Open Access

    New rectum dose surface mapping methodology to identify rectal subregions associated with toxicities following prostate cancer radiotherapy

    by Artemis Bouzaki, Dylan Green, Marcel van Herk, Jane Shortall, Tanuj Puri, Sarah Kerns, David Azria, Marrie-Pierre Farcy-Jacquet, Jenny Chang-Claude, Ananya Choudhury, et al.


  • Open Access

    Editorial: Quantitative [18F]NaF PET in metastatic and metabolic bone diseases

    by Tanuj Puri, Amelia E. Moore, Abhishek Mahajan, Alan McWilliam, Marie H. Vrist, Glen M. Blake

    Of bone biopsy, which is an invasive, uncomfortable, and painful technique for patients. Even though, biochemical markers of bone formation and resorption in serum or urine provide a rapid and simple way of measuring whole-body skeletal metabolism, which can be used to verify treatment response within a few weeks after the commencement of treatment. However, unlike imaging methods such as [ 18 F]NaF PET-CT, they are unable to provide site-specific information at clinically important sites susceptible to fractures, such as the hip and spine.[ 18 F]NaF PET has proven useful in early-phase clinical trials of novel anti-fracture drugs, helping to mitigate late attrition rates. The articles published within this research topic delve into the nuances of [ 18 F]NaF PET, exploring its applications in metastatic and metabolic bone diseases. These articles not only highlight current advancements in the field but also set the stage for future directions. Here, we summarise insights from four articles that contribute to the expanding landscape of knowledge in this field.In an introductory review article, Puri et al. underscore the capacity of [ 18 F]NaF PET to noninvasively estimate changes in regional bone metabolism far earlier than the structural alterations detected by conventional methods such as dual-energy x-ray absorptiometry (DXA). The review discusses the two commonly used approaches to applying [ 18 F]NaF PET to study bone metabolism: the measurement of [ 18 F]NaF bone plasma clearance (Ki) and the standardised uptake value (SUV). Crucially, it highlights instances where a decoupling of the correlation between SUV and Ki may occur, emphasising the greater reliability of Ki measurement when a bone lesion or its treatment is potent enough to alter the area under the arterial input function curve compared to that observed prior to treatment. Furthermore, the article discusses advancements in PET data methodologies, such as shortened scan times and a reduced number of blood samples, enhancing the practicality of [ 18 F]NaF PET outside the research setting and fostering its adoption for a wider variety of clinical applications.In the second article by Theil and co-authors, the focus shifts to the meticulous evaluation of image-derived input functions in patients with chronic kidney disease mineral and bone disorder (CKD-MBD). The article systematically analyses and compares multiplicative and additive methods of deriving semi-population arterial input functions, suggesting that the resulting AUCs are within 12% of each other and yield similar Ki values. Furthermore, the article suggests that input function recovery coefficients correlate with the volume and location of the region within the artery from which these values are derived. Finally, the article recommends the use of a consistent methodology for deriving the input function to minimise the variation in the assessment of bone metabolism between diverse patient population studies and to improve the differentiation between states of low and high bone turnover rates within the CKD-MBD population. In the fourth article, Watkins et al. explore the impact of dynamic [ 18 F]NaF PET scan duration on kinetic uptake parameters in the knee with and without osteoarthritis. Addressing practical concerns related to patient comfort and scan throughput, the study demonstrates the feasibility of shorter scan times while retaining accuracy in estimating bone perfusion and metabolism. This finding holds significant implications for improving the efficiency of PET scans, reducing patient burden, and enhancing overall clinical workflow.As we navigate through these articles, a comprehensive understanding of the potential applications of [ 18 F]NaF PET in bone diseases emerges. A frequent theme that emerges from this Research Topic is that a standardised methodology is required for deriving the input function and the corresponding Ki values before the technique of quantitative [ 18 F]NaF PET can be translated into the clinic. For this reason, we have previously developed and shared a simplified method using a static 4-min [ 18 F]NaF PET scan at a single bed-position with 2-3 venous blood samples (FIGURE 1) and provided a spreadsheet for calculating the bone plasma clearance (Ki) values (1).In conclusion, the collection of articles presented in this Frontiers Research Topic underscores the transformative potential of [ 18 F]NaF PET in the realm of bone diseases. From refining quantitative methodologies to assessing treatment responses, these studies contribute significantly to the evolving landscape of applying PET imaging to estimate bone metabolism. As research continues to unfold, the integration of [ 18 F]NaF PET into routine clinical practice will help revolutionise our approach to diagnosing and monitoring the treatment response in bone diseases, ultimately improving patient outcomes.

  • Open Access

    Utility of a simplified [18F] sodium fluoride PET imaging method to quantify bone metabolic flux for a wide range of clinical applications

    by Tanuj Puri, Michelle L. Frost, Amelia E. B. Moore, Ananya Choudhury, Sobhan Vinjamuri, Abhishek Mahajan, Claire Fynbo, Marie Vrist, Jørn Theil, Kalevi Kairemo, et al.

    We review the rationale, methodology, and clinical utility of quantitative [18F] sodium fluoride ([18F]NaF) positron emission tomography-computed tomography (PET-CT) imaging to measure bone metabolic flux (Ki, also known as bone plasma clearance), a measurement indicative of the local rate of bone formation at the chosen region of interest. We review the bone remodelling cycle and explain what aspects of bone remodelling are addressed by [18F]NaF PET-CT. We explain how the technique works, what measurements are involved, and what makes [18F]NaF PET-CT a useful tool for the study of bone remodelling. We discuss how these measurements can be simplified without loss of accuracy to make the technique more accessible. Finally, we briefly review some key clinical applications and discuss the potential for future developments. We hope that the simplified method described here will assist in promoting the wider use of the technique.


  • Open Access

    Input function and modeling for determining bone metabolic flux using [18F] sodium fluoride PET imaging: A step‐by‐step guide

    by Tanuj Puri, Michelle L. Frost, Amelia E. B. Moore, Gary J. R. Cook, Glen M. Blake

    Studies of skeletal metabolism using measurements of bone metabolic flux (Ki) obtained with [18F] sodium fluoride ([18F]NaF) positron emission tomography (PET) scans have been used in clinical research for the last 30 years. The technique has proven useful as an imaging biomarker in trials of novel drug treatments for osteoporosis and investigating other metabolic bone diseases, including chronic kidney disease mineral and bone disorder. It has also been shown to be valuable in metastatic bone disease in breast cancer patients and may have potential in other cancer types, such as prostate cancer, to assess early bone fracture risk. However, these studies have usually required a 60‐min dynamic PET scan and measurement of the arterial input function (AIF), making them difficult to translate into the clinic for diagnostic purposes. We have previously proposed a simplified method that estimates the Ki value at an imaging site from a short (4‐min) static scan and venous blood samples. A key advantage of this method is that, by acquiring a series of static scans, values of Ki can be quickly measured at multiple sites using a single injection of the tracer. To date, the widespread use of [18F]NaF PET has been limited by the need to measure the AIF required for the mathematical modeling of tracer kinetics to derive Ki and other kinetic parameters. In this report, we review different methods of measuring the AIF, including direct arterial sampling, the use of a semi‐population input function (SP‐AIF), and image‐derived input function, the latter two requiring only two or three venous blood samples obtained between 30 and 60 min after injection. We provide an SP‐AIF model and a spreadsheet for calculating Ki values using the static scan method that others can use to study bone metabolism in metabolic and metastatic bone diseases without requiring invasive arterial blood sampling. The method shortens scan times, simplifies procedures, and reduces the cost of multicenter trials without losing accuracy or precision.


  • Open Access

    Comparison of ten predictive equations for estimating lean body mass with dual-energy X-ray absorptiometry in older patients

    by Tanuj Puri, Glen M Blake

    Objectives: White fat contributes to body weight (BW) but accumulates very little [18F]fluorodeoxyglucose ([18F]FDG) in the fasting state. As a result, higher standardised uptake values normalised to BW (SUV) are observed in non-fatty tissue in obese patients compared to those in non-obese patients. Therefore, SUV normalised to lean body mass (SUL) that makes tumour uptake values less dependent on patients’ body habitus is considered more appropriate. This study aimed to assess ten mathematical equations to predict lean body mass (LBM) by comparison with dual-energy X-ray absorptiometry (DXA) as the reference method. Methods: DXA-based LBM was compared with ten equation-based estimates of LBM in terms of the slope, bias and 95% limits of agreement (LOA) of Bland-Altman plots, and Pearson correlation coefficients (r). Data from 747 men and 811 women aged 60–65 years were included. Results: Gallagher’s equation was optimal in males (slope = 0.13, bias = −2.4 kg, LOA = 12.8 kg and r = 0.900) while Janmahasatian’s equation was optimal in females (slope = 0.14, bias = −0.9 kg, LOA = 10.7 kg and r = 0.876). Janmahasatian’s equation performed slightly better than Gallagher’s in the pooled male and female data (slope = 0.00, bias = −1.6 kg, LOA = 12.3 kg and r = 0.959). Conclusions: The Gallagher and Janmahasatian equations were optimal and almost indistinguishable in predicting LBM in subjects aged 60–65 years. Advances in knowledge: Determination of the optimum equation for predicting lean body mass to improve the calculation of SUL for [18F]FDG PET quantification.